Kaufman Amends Lipella Pharma Stake

TL;DR

Kaufman updated his Lipella Pharma stake filing on 3/15/24. Watch this space.

AI Summary

On March 15, 2024, Jonathan H. Kaufman filed an amendment (No. 4) to Schedule 13D for Lipella Pharmaceuticals Inc. This filing indicates a change in beneficial ownership of the company's common stock. Kaufman's address is listed as c/o Lipella Pharmaceuticals Inc. in Pittsburgh, PA.

Why It Matters

This filing signals a potential shift in control or significant shareholder activity for Lipella Pharmaceuticals, which could impact its stock price and strategic direction.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant shareholder activity that can lead to volatility or strategic changes.

Key Numbers

• 4 — Amendment Number (Indicates this is the fourth update to the filing.)
• March 15, 2024 — Date of Event (The date triggering this filing amendment.)

Key Players & Entities

• Jonathan H. Kaufman (person) — Filing person
• Lipella Pharmaceuticals Inc. (company) — Subject company
• David E. Danovitch, Esq. (person) — Authorized to receive notices
• Sullivan & Worcester LLP (company) — Legal counsel

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• g084132_13da.htm (SC 13D/A) — 39KB
• 0001753926-24-000565.txt ( ) — 40KB

Security and Issuer

Item 1. Security and Issuer. The information contained in “Item 1. Security and Issuer.” of the Schedule 13D is not being amended by this Amendment No. 4. Item 2. Identity and Background. The information contained in “Item 2. Identity and Background.” of the Schedule 13D is not being amended by this Amendment No. 4.

Source or Amount of Funds or

Item 3. Source or Amount of Funds or Other Consideration. “Item 3. Source or Amount of Funds or Other Consideration.” of the Schedule 13D is hereby amended and restated in its entirety as follows: The Reporting Person beneficially owns 1,635,015 shares of Common Stock, consisting of (i) 888,849 shares of Common Stock which were acquired with personal funds from time to time, and (ii) 746,166 shares of Common Stock that may be issued upon the exercise of stock options owned by the Reporting Person that were awarded to him in his capacity as an executive officer and director of the Issuer.

Purpose of Transaction

Item 4. Purpose of Transaction. The information contained in rows (7), (8), (9), (10), (11) and (13) of the cover page of this Amendment No. 4 and the corresponding footnotes, and the information set forth in or incorporated by reference in Item 2, Item 3, Item 5 and Item 6 of this Amendment No. 4 is hereby incorporated by reference in its entirety into this Item 4 and reflect, among other holdings, the open market purchases by the Reporting Person of an aggregate of 55,000 shares of Common Stock between March 18, 2024 and March 19, 2024. Except as described above, the information contained in “Item 4. Purpose of Transaction.” of the Schedule 13D is not being amended by this Amendment No. 4.

Interest in Securities of the

Item 5. Interest in Securities of the Issuer. The responses to rows (7) through (13) of the cover page of this Amendment No. 4 and the corresponding footnotes are hereby incorporated by reference in their entirety in this Item 5. (a) See responses to Items 11 and 13 on the cover page. (b) See response to Rows (7), (8), (9) and (10) on the cover page. CUSIP No. 53630L100 Amendment No. 4 to Schedule 13D Page 4 of 5 Pages (c) Between March 18, 2024 and March 19, 2024, the Reporting Person purchased an aggregate of 55,000 shares of Common Stock in open market purchases. Except as otherwise set forth in the Schedule 13D, the Reporting Person has not, to the best of his knowledge, engaged in any transaction with respect to the Common Stock of the Issuer during the sixty days prior to the date of filing this Amendment No. 4. Except as described above, the information contained in “Item 5. Interest in Securities of the Issuer.” of the Schedule 13D is not being amended by this Amendment No. 4.

Contracts, Arrangements, Understandings

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. The information contained in “Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.” of the Schedule 13D is not being amended by this Amendment No. 4.

Material to be filed as Exhibits

Item 7. Material to be filed as Exhibits. The information contained in “Item 7. Material to be filed as Exhibits.” of the Schedule 13D is not being amended by this Amendment No. 4. CUSIP No. 53630L100 Amendment No. 4 to Schedule 13D Page 5 of 5 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: March 19, 2024 /s/ Jonathan H. Kaufman Name: Jonathan H. Kaufman

View Full Filing

View this SC 13D/A filing on SEC EDGAR